Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211631 | 0.85 | BRD4 (0.47) | BRD4GSK3BPDK1HSP90AA1HSP90AB1 | |
| SCHEMBL4403649 | 0.77 | NOS3 (0.38) | BRD4CCR1CCR5CCR8 | |
| SCHEMBL4403657 | 0.76 | BRD4 (0.49) | BRD4 | |
| SCHEMBL8488240 | 0.74 | CHUK (0.48) | — | |
| SCHEMBL17211632 | 0.74 | BRD4 (0.55) | BRD4CCR1CCR5CCR8 | |
| SCHEMBL31370721 | 0.74 | BRD4 (0.35) | BRD4CCR1CCR5CCR8GSK3B | |
| SCHEMBL18359212 | 0.74 | LRRK2 (0.38) | BRD4CCR1CCR5CCR8 | |
| SCHEMBL19221990 | 0.74 | CHRNA7 (0.41) | BRD4CCR1CCR5CCR8 | |
| SCHEMBL15344926 | 0.73 | ELANE (0.50) | GSK3BDYRK1A | |
| SCHEMBL15345072 | 0.72 | SLC6A4 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447093-B2 | 3,5-diarylazaindoles as DYRK1A protein inhibitors for the treatment of cognitive deficiencies associated with Down's syndrome and with Alzheimer's disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2016-09-20 | — | — | US | disclosed |
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307492-A1 | 3,5-Diarylazaindoles as DYRK1A Protein Inhibitors for the Treatment of Cognitive Deficiencies Associated with Down's Syndrome and with Alzheimer's Disease | DYRK1A, DYRK3, DYRK2 | BRD4 213/4885CRHR1 330/4885CCR1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.